Related scientific articles (all)

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial.

Authors : Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P
Year : 2016
Journal : Ann Oncol
Volume : 27(4)
Pages : 619-24

What is the role of informed decision-making?

Authors : Pondé N, Dal Lago L, Azim HA Jr
Year : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(9)
Pages : 893

Frequent incidence of BARD1 truncating mutations in germline DNA from triple negative breast cancer patients.

Authors : De Brakeleer S, De Grève J, Desmedt C, Joris S, Sotiriou C, Piccart-Gebhart M, Pauwels I, Teugels E
Year : 2016
Journal : Clin. Genet.
Volume : 89(3)
Pages : 336-40.

Will Testicular Germ Cell Tumors Remain Untargetable?

Authors : Aoun F, Kourie HR, Albisinni S, Roumeguère T
Year : 2016
Journal : Target Oncol
Volume : 11(6)
Pages : 711-21

Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries.

Authors : Antoine C, Ameye L, Paesmans M, de Azambuja E, Rozenberg S
Year : 2016
Journal : Maturitas
Volume : 84
Pages : 81-8

70-Gene Signature in Early-Stage Breast Cancer.

Authors : van’t Veer LJ, Rutgers EJT, Piccart-Gebhart M
Year : 2016
Journal : N Engl J Med
Volume : 375
Pages : 2200-2201

Why balls are not put inside the basket? A reflection on testicular cancer clinical trial design.

Authors : Kourie HR, Aoun F
Year : 2016
Journal : Invest New Drugs
Volume : 34(4)
Pages : 513-4

Biomarkers for adverse events associated with immune checkpoint inhibitors.

Authors : Kourie HR, Paesmans M, Klastersky J
Year : 2016
Journal : Biomark Med
Volume : 10
Pages : 1029-31

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Authors : Awada A, Cortés J, Martín M, Aftimos P, Oliveira M, López-Tarruella S, Espie M, Lardelli P, Extremera S, Fernández-García EM, Delaloge S
Year : 2016
Journal : Clin Breast Cancer
Volume : 16(5)
Pages : 364-71

Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Authors : Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S
Year : 2016
Journal : Nat Rev Clin Oncol
Volume : 13(4)
Pages : 228-41

Breast cancer in 2015: Academic research sheds light on issues that matter to patients.

Authors : Piccart-Gebhart M, Gingras I
Year : 2016
Journal : Nat Rev Clin Oncol
Volume : 13
Pages : 67-8

Testicular germ cell tumor: Short and long-term side effects of treatment among survivors.

Authors : Gil T, Sideris S, Aoun F, Van Velthoven R, Sirtaine N, Paesmans M, Ameye L, Awada A, Devriendt D, Peltier A
Year : 2016
Journal : Mol Clin Oncol
Volume : 5
Pages : 258-264

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Year : 2016
Journal : Ann Oncol
Volume : 27(8)
Pages : 1519-25

Response to 'Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?'

Authors : Goldrat O, Demeestere I, Azim HA
Year : 2016
Journal : Eur J Cancer
Volume : 54
Pages : 165-6

Phosphoethanolamine and the danger of unproven drugs.

Authors : Pondé N, de Azambuja E, Ades F
Year : 2016
Journal : Ecancermedicalscience
Volume : 10
Pages : 681

Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

Authors : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart-Gebhart M
Year : 2016
Journal : Ann Oncol
Volume : 27
Pages : 203-5

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs.

Authors : Fadoukhair Z, Zardavas D, Chad MA, Goulioti T, Aftimos P, Piccart-Gebhart M
Year : 2016
Journal : Oncogene
Volume : 35(14)
Pages : 1743-9

Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.

Authors : Kourie HR, Ameye L, Paesmans M, Bron D
Year : 2016
Journal : Ann Hematol
Volume : 95(12)
Pages : 2105-2106

Pancreatic small cell cancer.

Authors : El Rassy E, Tabchi S, Kourie HR, Assi T, Chebib R, Farhat F, Kattan J
Year : 2016
Journal : Clin Res Hepatol Gastroenterol
Volume : 40
Pages : 276-80

RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors.

Authors : Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sanchez V, Sanders M, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gomez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM
Year : 2016
Journal : Clin Cancer Res
Volume : 22(6)
Pages : 1499-509